Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Novel Non-Covalent Hits Against GPX4 Identified Using the RiDYMO® Reinforced Dynamics Platform of DP Technology


      News provided by

      DP Technology

      Aug 01, 2024, 05:00 ET

      Share this article

      Share this article


      Research on ferroptosis is gaining momentum, but the development of small molecule inhibitors faces numerous challenges

      BEIJING, Aug. 1, 2024 /PRNewswire/ -- Glutathione peroxidase 4 (GPX4) is recognized as a critical regulator of ferroptosis, playing a significant role in lipid and amino acid metabolism, as well as influencing cellular aging, oncogenesis, and cell death [1]. Targeting GPX4-mediated ferroptosis presents a promising therapeutic strategy, particularly in the treatment of cancer [2].

      Continue Reading
      Fig. 1 Crystal structure of GPX4 protein in complex with ML162[3] (PDB ID: 6HKQ) and existing covalent inhibitors.
      Fig. 1 Crystal structure of GPX4 protein in complex with ML162[3] (PDB ID: 6HKQ) and existing covalent inhibitors.
      Fig. 2 Enhanced Sampling of GPX4 Protein with RiD
      Fig. 2 Enhanced Sampling of GPX4 Protein with RiD
      Fig. 3 Molecular dynamics simulations combined with the organic solvent probe to induce the discovery of a new pocket in GPX4.
      Fig. 3 Molecular dynamics simulations combined with the organic solvent probe to induce the discovery of a new pocket in GPX4.
      Fig. 4 Results of ML162 and screened molecules in GPX4 enzymatic assay (A), SPR assay (B), and ROS assay (C)
      Fig. 4 Results of ML162 and screened molecules in GPX4 enzymatic assay (A), SPR assay (B), and ROS assay (C)
      Fig. 5 The workflow of identifying novel non-covalent hits against GPX4 using the RiDYMO® Reinforced Dynamics Platform
      Fig. 5 The workflow of identifying novel non-covalent hits against GPX4 using the RiDYMO® Reinforced Dynamics Platform
      DP Technology
      DP Technology
      DP Technology
      DP Technology

      Despite its potential, GPX4's flat surface presents significant challenges, as it lacks distinct druggable pockets (Fig. 1A). Current inhibitors of GPX4 with cellular activity typically covalently bind to the selenocysteine residue at position 46, leading to poor selectivity and high toxicity (Fig. 1B).

      Given this background, it is crucial to explore potential cryptic pockets or allosteric sites on GPX4 that could influence its biological function.

      AI-Powered RiDYMO  Platform Identifies Novel Binding Sites and Non-covalent Inhibitors

      "Our strategy for developing GPX4 inhibitors centers on identifying cryptic pockets that offer improved druggability," stated Dr. Xiaomin Zhang, Head of Drug Discovery at DP Technology. "The company's AI for Science-based RiDYMO platform employs molecular dynamics simulations to reveal conformational changes within proteins, facilitating the discovery of novel druggable pockets. The non-covalent molecules developed using these pockets demonstrate enzyme inhibition and cellular activity comparable to established covalent controls, while exhibiting improved druggability. This highlights the RiDYMO platform's significance in drug discovery, particularly for challenging targets."

      The workflow utilized by DP Technology's research team for this project encompassed the following steps:

      1.      Protein Conformation Sampling: The GPX4 protein was simulated using Reinforced Dynamics (RiD)[4]. As illustrated in Fig. 2, RiD surpasses traditional Molecular Dynamics (MD) by more effectively exploring the protein's conformational space, revealing additional metastable conformations and cryptic sites (with pink areas indicating amino acids concealed within the protein).

      2.      Induction of Druggable Pockets: After identifying hidden sites, we conducted further exploration and induction of these pockets using organic solvent probes. As shown in Fig. 3, these organic solvent probes facilitated the formation of deeper small molecule binding pockets on the previously flat surface of the protein.

      3.      Molecule Screening and Validation: High-throughput virtual screening was conducted on these pockets using the Uni-Dock[5] from DP Technology's Hermite drug design platform. The non-covalent molecules DP018 and DP029 exhibited micromolar-level inhibition of GPX4 enzymatic activity (Fig. 4A), comparable to the covalent inhibitor ML162. Surface Plasmon Resonance (SPR) experiments confirmed the direct binding of non-covalent molecules to GPX4 with micromolar affinity (Fig. 4B). Additionally, results from the ROS assay (Fig. 4C) indicate that these non-covalent molecules effectively induce ferroptosis in cells.

      4.      Summary: James et al. highlighted four limitations of structural biology in drug development in their publication in Cell [6]. One of these challenges is that protein wiggling and jiggling are crucial but challenging to model experimentally and computationally, future drug design will unlock methods based on the ensemble of structures. In our research, we conducted a comprehensive analysis of the dynamics of the protein's backbone and side chains using RiD simulation and organic solvent probing. By effectively identifying two druggable pockets and conducting high-throughput virtual screening of compound libraries totaling approximately ten million compounds, we discovered around ten active non-covalent inhibitor molecules. Notably, two of these inhibitors demonstrated high enzymatic activity and strong binding affinity, with their capacity to induce ferroptosis further validated at the cellular level.

      Making Proteins "Move" – The RiDYMO® Reinforced Dynamics Platform

      The RiDYMO® platform integrates various AI and physical algorithms, dedicated to the development of drugs for "undruggable" targets and "best-in-class" molecules. As one of its core algorithms, Reinforced Dynamics (RiD)[4] has a significant advantage in the sampling efficiency of molecular dynamics simulation. By fully leveraging the high-dimensional representation capabilities of neural networks, RiD can efficiently capture dynamic conformational changes in complicated biomolecular systems. Previously, the core RiD algorithm of the platform was published in Nature Computational Science. The study demonstrated that RiD could achieve a more comprehensive free energy surface within 1.86 μs, compared to 100 μs required by traditional MD methods, representing nearly a hundredfold increase in efficiency.

      The RiDYMO® platform studies the dynamics of biological systems, revealing cryptic binding sites across challenging systems, including protein-protein interactions (PPIs), intrinsically disordered proteins (IDPs), membrane proteins, and RNA. Its effectiveness has been validated on targets such as the COPI protein, MCL1 protein, c-Myc protein, GPX4 protein, NMDA protein, Nav1.8 protein, and c-Myc RNA.

      We look forward to collaborating with trusted partners to advance these initiatives through all stages of development, including hit, lead, PCC, and IND. For collaboration inquiries or additional information, please contact [email protected].

      About DP Technology

      DP Technology is a global leader in the "AI for Science" research paradigm, where AI learns scientific principles and data, then tackles key challenges in scientific research and industrial R&D.

      We've developed the "DP Particle Universe," a suite of advanced pre-trained models that seamlessly connect cutting-edge research with real-world industrial applications. Our software suite includes:

      • Bohrium® Scientific Computing Space Station
      • Hermite® Computational Drug Design Platform
      • RiDYMO® Hit Discovery Platform
      • Piloteye® Battery Design Automation Platform

      Together, these platforms form a robust foundation for industrial innovation and an open ecosystem for AI in science, fostering advancements in key areas such as drug discovery, energy, material science, and information technology.

      Relying on DP Technology's advanced Reinforced Dynamics Platform, RiDYMO®, we have set up a world-leading hit discovery system. The team has established external collaborations and built up a strong internal pipeline, focusing on three areas: CNS, oncology, and autoimmune diseases.

      Reference

      [1] Stockwell, B. R. (2022). Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell, 185(14), 2401-2421.

      [2] Wang, F., & Min, J. (2021). DHODH tangoing with GPX4 on the ferroptotic stage. Signal Transduction and Targeted Therapy, 6(1), 1-2.

      [3] Moosmayer, D., Hilpmann, A., Hoffmann, J., Schnirch, L., Zimmermann, K., Badock, V., ... & Hillig, R. C. (2021). Crystal structures of the selenoprotein glutathione peroxidase 4 in its apo form and in complex with the covalently bound inhibitor ML162. Acta Crystallographica Section D: Structural Biology, 77(2), 237-248.

      [4] Wang, D., Wang, Y., Chang, J., Zhang, L., Wang, H. & E, W. (2022). Efficient sampling of high-dimensional free energy landscapes using adaptive reinforced dynamics. Nature Computational Science, 2(1), 20-29.

      [5] Yu, Y., Cai, C., Wang, J., Bo, Z., Zhu, Z., & Zheng, H. (2023). Uni-Dock: GPU-accelerated docking enables ultralarge virtual screening. Journal of chemical theory and computation, 19(11), 3336-3345.

      [6] Fraser, J. S., & Murcko, M. A. (2024). Structure is beauty, but not always truth. Cell, 187(3), 517-520.

      SOURCE DP Technology

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.